U.S., Jan. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07332507) titled 'Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma' on Jan. 09.
Brief Summary: This phase Ib trial tests the safety, side effects, and best dose, as well as the effectiveness of teclistamab in treating patients with plasmablastic lymphoma that has come back after a period of improvement (recurrent) or that has not responded to previous treatment (refractory). Teclistamab is a bispecific antibody that can bind to two different antigens at the same time. Teclistamab binds to B-cell maturation antigen (BCMA), a protein found on some B-cells and myeloma cells, and CD3 on T-cells (a type of white blood cell) and may in...